Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New funding for development of mucosal vaccines based on nanoparticle technology

08.10.2013
The Knut and Alice Wallenberg Foundation will give a little over SEK 16 million to the development of new, highly-efficient mucosal vaccines.

The vaccines will be drinkable or given as a nasal spray. Professor Nils Lycke at MIVAC at the Sahlgrenska Academy will in cooperation with researchers at Chalmers University of Technology and Lund University, combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

According to world-health organizations, vaccination programs against the most serious infectious diseases represent the single-most important measure to improve global health and prevent debilitating disease. However, as most vaccines are injected and given by highly-trained healthcare personnel they are more difficult to administer in many parts of the world and the use of syringes, which may be reused, increases the risk for blood born contamination and spread of infection.

Also traditional mass vaccination in case of pandemic spread of infection, as for example with influenza, is very costly and difficult to undertake with traditional vaccines.

Mucosal vaccines, drinkable or nasal spray vaccines, have many practical advantageous, but few mucosal vaccines are commercially available today. This is because mucosal vaccines need powerful adjuvants and finding effective formulations that protect the vaccine components from degradation in harsh mucosal environments, such as the gut intestine.

The adjuvant is the critical component of most vaccines that greatly enhances the immune response. For mucosal vaccines traditional adjuvants are not effective. Another advantage of mucosal vaccines is that the immune defense is located to the mucosal membranes that are the port of entry for most pathogens, including tuberculosis, influenza and HIV.

The research team has received funding from the Foundation to develop the next generation of effective mucosal vaccines based on their expertise in vaccine adjuvant and lipid nanoparticle research.

“We are now taking a unique and pioneering step towards a universal platform for mucosal vaccines by developing a new targeted lipid nanoparticle vaccine that combines knowledge from different disciplines,” says Nils Lycke.

The team of researchers to undertake the project are professors Nils Lycke and Mary-Jo Wick at the Sahlgrenska Academy, William Agace at Lund University, Fredrik Höök and Marta Bally at Chalmers.

The research group will take a conceptually new approach to combining effective adjuvants with lipid nanoparticles to direct these complexes to the dendritic cells in the mucosal membranes.

These cells are the key target for the next generation of mucosal vaccines and responsible for initiating vaccine immune responses. The researchers have complementing expertise to solve the problems of how to combine all the expected properties of the mucosal vaccine in one particle.

“Thanks to a flexible particle design, and extensive experience with a patented adjuvant system we hope to be successful in our efforts” says Nils Lycke. If successful, the next generation of mucosal vaccines will have a major impact not only on vaccine prevention of infections, but also on global health ” says Nils Lycke.

“The idea is unique in several respects. No one has previously combined these components in a particle and no one has, in a structured manner, optimized the lipid particles to make mucal inoculations effective.”

The research project brings together four internationally successful research leaders with expertise in immunology, nano-biotechnology and vaccine development.

For further information, please contact:
Professor Nils Lycke at the Sahlgrenska Academy, head of the MIVAC (Mucosal Immunity and Vaccines) research center
Tel. +46 (0)70-6711641, +46 (0)31-786 63 21
e-mail nils.lycke@microbio.gu.se
William Agace, Professor at Lund University
046-222 04 16
William.Agace@med.lu.se
Fredrik Höök, Professor, Chalmers
031-772 61 30
fredrik.hook@chalmers.se

Torsten Arpi | idw
Further information:
http://www.wallenberg.com/kaw/

More articles from Health and Medicine:

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>